GLP-1 agonists is currently approved as second/third-line therapy for T2DM patients with inadequate glycaemic control (HbA1c 7.0 or 53 mmol/mol) despite lifestyle modifications and first-line antihyperglycaemics (metformin/sulfonylurea/insulin)
Perry A, Roberts G, Mitchell PB, Breakspear M
"Potential role of N -acetylcysteine in the management of substance use disorders"
Last reviewed: June 24, 2026 Last updated: June 24, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Patients Seeking Established Treatment Options Tirzepatide may be a strong fit for patients looking for a treatment already integrated into medical weight management programs